Revvity Navigates $25 Million Tariff Headwind While Growing Revenue to $2.86 Billion
Revvity, Inc.Description
What this story covers
Revvity's 2025 10-K reveals 4% revenue growth to $2.86 billion, driven by Life Sciences software and Diagnostics. Despite $25 million in tariff costs and China headwinds, the company maintained strong liquidity and aggressive shareholder buybacks.
Story snapshot
CompanyRevvity, Inc.
TickerRVTY
VariantStandard detailed
Duration12:02
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000031791-26-000012
Sources1
Full Story Script
Content not available for this story.